Trulicity contains dulaglutide, a long-acting glucagon-like peptide‑1 (GLP‑1) analogue with ~90% homology to human GLP‑1, linked to an IgG4 Fc fragment to extend its half‑life (~4.7 days), enabling once-weekly subcutaneous dosing.

Mechanism of Action
Dulaglutide mimics GLP‑1 by:
• Stimulating glucose-dependent insulin secretion
• Inhibiting excessive glucagon release
• Slowing gastric emptying
These combined actions improve glycaemic control and promote a feeling of fullness.

In Summary
Trulicity (dulaglutide) offers a convenient once-weekly treatment option that improves glycaemic control, supports modest weight loss, and lowers cardiovascular risk in type 2 diabetes. Its ease of use and efficacy make it a popular choice, though close attention is required for gastrointestinal side effects, thyroid risk, and compatibility with other medications. Regular follow-up ensures both safety and optimal therapeutic benefit.